Table 1.
Clinical and pathological features of patients with end-stage heart failure due to dilated cardiomyopathy before and after heart transplantation
| Before Htx | Months after Htx (Biopsy grading) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Heart transplant patients | Sex | Age (years) | NYHA class | LVEDD | LVEF | 1 | 3 | 6 | 12 | |||||||||
| #1 | M | 55 | IV | 81 | 25 | 0 | 0 | 0 | 0 | |||||||||
| #2 | M | 48 | III | 94 | 15 | I | I | I | I | |||||||||
| #3 | M | 53 | III | 90 | 15 | 0 | 0 | 0 | 0 | |||||||||
| #4 | M | 64 | III | 72 | 24 | I | II | II | II | |||||||||
| #5 | M | 52 | III | 92 | 27 | 0 | 0 | 0 | 0 | |||||||||
| #6 | M | 61 | III | 102 | 26 | 0 | III | I | 0 | |||||||||
| #7 | M | 53 | IV | 79 | 14 | I | II | II | 0 | |||||||||
| #8 | M | 51 | III | 83 | 26 | 0 | 0 | 0 | I | |||||||||
| #9 | M | 46 | III | 80 | 29 | 0 | I | 0 | 0 | |||||||||
| #10 | M | 51 | III | 68 | 25 | II | 0 | 0 | 0 | |||||||||
| #11 | M | 46 | IV | 86 | 31 | I | I | 0 | 0 | |||||||||
M: male; Htx: heart transplantation; NYHA class: New York Heart Association functional class; LVEDD: LV end-diastolic dimension (mm); LVEF: LV ejection fraction (%). Biopsy grading: 0, no rejection; I, focal or diffuse but sparse infiltrate without necrosis; II, 2 or more foci of infiltrate with associated myocyte damage; III, diffuse infiltrate with multifocal myocyte damage.